Schizophrenia research · 2024
A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia.
СтатьяСистематический обзорNetwork Meta-AnalysisНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wright Abigail C, McKenna Avery, Tice Jeffrey A, Rind David M, Agboola Foluso
Аннотация
BACKGROUND: Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.
METHODS: We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3-8 weeks) that enrolled adults with schizophrenia. We compared KarXT to aripiprazole, risperidone, and olanzapine. We sought evidence for symptoms (Positive and Negative Symptoms Scale [PANSS]), weight gain, and all-cause discontinuation.
RESULTS: We included 33 trials with 7193 participants. For total, positive, and negative symptoms, KarXT and the three antipsychotics were significantly more efficacious than placebo (mean difference [MD] vs placebo range for total symptoms: -10.67 to -8.05; positive symptoms: -3.46 to -2.53; negative symptoms: -1.99 to -1.44) but not significantly different from each other. KarXT was ranked as least likely to lead to weight gain. This was significant versus risperidone (-2.06 kg; 95 % CrI: -3.28, -0.87) and olanzapine (-2.86 kg; 95 % CrI: -3.97, -1.82). However, KarXT was ranked highest for all-cause discontinuation. This was significant versus risperidone (RR: 0.64; 95 % CrI: 0.46, 0.89) and olanzapine (RR: 0.6; 95 % CrI: 0.44, 0.83).
CONCLUSIONS: KarXT and commonly used antipsychotics were more efficacious than placebo at reducing symptoms, but there were no clear differences in short-term efficacy among the active interventions. KarXT was less likely to cause weight gain, an important outcome for those with schizophrenia; short-term data do not permit evaluation of the risk for tardive dyskinesia. Long-term data are needed.
METHODS: We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3-8 weeks) that enrolled adults with schizophrenia. We compared KarXT to aripiprazole, risperidone, and olanzapine. We sought evidence for symptoms (Positive and Negative Symptoms Scale [PANSS]), weight gain, and all-cause discontinuation.
RESULTS: We included 33 trials with 7193 participants. For total, positive, and negative symptoms, KarXT and the three antipsychotics were significantly more efficacious than placebo (mean difference [MD] vs placebo range for total symptoms: -10.67 to -8.05; positive symptoms: -3.46 to -2.53; negative symptoms: -1.99 to -1.44) but not significantly different from each other. KarXT was ranked as least likely to lead to weight gain. This was significant versus risperidone (-2.06 kg; 95 % CrI: -3.28, -0.87) and olanzapine (-2.86 kg; 95 % CrI: -3.97, -1.82). However, KarXT was ranked highest for all-cause discontinuation. This was significant versus risperidone (RR: 0.64; 95 % CrI: 0.46, 0.89) and olanzapine (RR: 0.6; 95 % CrI: 0.44, 0.83).
CONCLUSIONS: KarXT and commonly used antipsychotics were more efficacious than placebo at reducing symptoms, but there were no clear differences in short-term efficacy among the active interventions. KarXT was less likely to cause weight gain, an important outcome for those with schizophrenia; short-term data do not permit evaluation of the risk for tardive dyskinesia. Long-term data are needed.